ACRS biotech catalysts & pipeline

ACLARIS THERAPEUTICS INC · Data as of 2026-10-27

Upcoming catalysts

next-generation JAK-Sparing ITK Inhibitor — IND submission

H2 2026

Announced Intent to File Initial Investigational New Drug (IND) Application for Next-Generation JAK-Sparing ITK Inhibitor in the Second Half of 2026: Aclaris' next-generation ITK-selective inhibitors have extended half-lives and show complete ITK occupancy at very low doses.

Source filing

ATI-9494 — IND submission

Q4 2026

We expect to file an IND application for ATI-9494 in the fourth quarter of 2026.

Source filing

bosakitug — Topline data

Q4 2026

On Track for Expected Fourth Quarter 2026 Readout of Top Line Results from Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug: Enrollment is complete in this randomized, double-blind, placebo-controlled Phase 2 trial designed to evaluate bosakitug in 109 patients with AD.

Source filing

undisclosed BsAb — IND submission

2027

Targeting first IND from bispecific antibody development efforts in 2027

Source filing

Explore the free biotech catalyst calendar